2009
Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study.
Collins L, Collins L, Gelber S, Gelber S, Ruddy K, Ruddy K, Tamimi R, Tamimi R, Come S, Come S, Marotti J, Marotti J, Schapira L, Schapira L, Kereakoglow S, Brachtel E, Brachtel E, Winer E, Winer E, Partridge A, Partridge A. Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. Cancer Research 2009, 69: 6007-6007. DOI: 10.1158/0008-5472.sabcs-09-6007.Peer-Reviewed Original ResearchYoung Women's Breast Cancer StudyBreast Cancer StudyPoor prognostic featuresBasal-like carcinomasPathologic featuresBreast cancerYoung womenHER2 positivityPrognostic featuresTumor stageTumor necrosisER/PR negativityMulti-center prospective cohortInvasive breast cancerClinico-pathologic featuresHER2-positive tumorsCancer studiesHigh tumor gradeHigher tumor stageHigh-grade tumorsBasal-like phenotypeBiomarker expression patternsLogistic regression modelsPR negativityClinical characteristics
2007
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer. Clinical Cancer Research 2007, 13: 1198-1207. PMID: 17317830, DOI: 10.1158/1078-0432.ccr-06-1304.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleGenes, erbB-2HumansMalePredictive Value of TestsPreoperative CareReceptor, ErbB-2TrastuzumabVinblastineVinorelbineConceptsPathologic complete responsePreoperative trastuzumabBreast cancerClinical responseComplete responseStage II/III breast cancerHER2-positive early breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Clinical complete responseEarly breast cancerGrowth factor receptor 2Estrogen receptor statusPositive breast cancerPredictors of responseBasal-like phenotypeInsulin-like growthFactor receptor 2Predictors of resistanceReceptor membrane expressionExtremes of responseGrowth factor pathwaysLow response rateGrowth factor receptorPreoperative treatment